Rich Pharmaceuticals, Inc., a biopharma company focused oncology therapies, has selected IND 2 Results, LLC, (I2R) of Atlanta GA, to serve as its CRO. I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin’s Lymphoma (HL). I2R will also assist in preparing the protocol for submission to the FDA.  I2R is also assisting the company in amending the Acute Myelocytic Leukemia (AML) protocol in prep...